Navigation Links
Kite Pharma announces positive results in patients with aggressive non-Hodgkin's lymphoma
Date:8/25/2014

  • 12 of 13 Total Evaluable Patients with Advanced B Cell Malignancies Had Complete Remissions (8 Patients) or Partial Remissions (4 Patients) Resulting in a 92% Objective Response Rate

  • 4 of 7 Evaluable Patients with Chemotherapy-Refractory Diffuse Large B-cell Lymphoma (DLBCL) Achieved Complete Remissions, 3 of Which Are Ongoing and 1 of Which Is Ongoing after 22 Months

  • The Results Have Been Published in the August 25, 2014 Issue of the American Society of Clinical Oncology's (ASCO) Journal of Clinical Oncology

  • The Results Support Kite's Plan to File an Investigational New Drug Application (IND) in the Fourth Quarter of 2014 to Initiate a Clinical Trial of Kite's Lead CAR-Based Product Candidate, KTE-C19, in Patients with DLBCL

Santa Monica, CA August 25, 2014 Kite Pharma, Inc., (NASDAQ: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer, today announced the publication of clinical results in a cohort of patients demonstrating the potential to treat aggressive non-Hodgkin's lymphoma with an anti-CD19 chimeric antigen receptor (CAR) T cell therapy. Kite's most advanced product candidate, KTE-C19, is an anti-CD19 CAR T cell therapy that involves genetically modifying a patient's T cells to express a CAR that is designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias.

The findings from an ongoing Phase 1-2a clinical trial funded by Kite and conducted by the Surgery Branch of the National Cancer Institute (NCI) demonstrated that in 12 out of 13 evaluable patients with advanced B-cell malignancies, administration of anti-CD19 CAR T cells resulted in complete remission in eight patients and partial remission in four patients, representing an overall objective response rate of 92%. Of seven evaluable patients with chemotherapy-refractory DLBCL,
'/>"/>

Contact: Justin Jackson
jjackson@burnsmc.com
212-213-0006 x327
Burns McClellan
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Seamless Medical Systems Announces the Launch of SNAP Express Rx™ to Enhance Pharmacy Patient Engagement and Clinical Care Coordination
2. The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins
3. Pleio, Inc. Expands Adherence Offerings For Retail Pharmacy
4. MedX Pharmacy Helps with Back to School Preparation
5. RevitaDERM® Psoriasis Treatment Now Available At Over 7,600 CVS/pharmacies
6. College of Pharmacy Has Banner Research Awards Year
7. Poland Pharmaceutical Industry Worth $15 Billion by 2020 Says a New Report Available at MarketOptimizer.org
8. Good Neighbor Pharmacy Invites Patients to Share Their "Good Neighbor Story"
9. Byetta Lawsuit News: Bernstein Liebhard LLP Notes British Columbia's Recent Decision to Discontinue Incretin Mimetic Drug Coverage from PharmaCare Program
10. Global Egg Phosphatidylcholine Market by Application (Cosmetic, Pharmaceutical, Dietary Supplements) is Expected to Reach USD 12.2 Million by 2020
11. Kirby Lester Pharmacy Robot Users: 97% Report Improved Operating Efficiency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... They say a picture is ... health conditions, pictures and medical art can be essential. StayWell, a health solutions company, ... Krames Patient Education solutions have been used by physicians and other health care providers ...
(Date:8/4/2015)... Farmingdale, New York (PRWEB) , ... August 04, ... ... for exceptional dietary supplement manufacturing, label design, product packaging, and fulfillment services, joined ... Workplace Challenge. The event was held on Tuesday, July 28th at Jones ...
(Date:8/4/2015)... Morristown & Montclair, NJ (PRWEB) , ... August 04, 2015 , ... ... certificate program in Arts and Health, the first of its kind in New Jersey, ... The University’s College of the Arts and Graduate School partnered with Atlantic Health System, ...
(Date:8/4/2015)... Las Vegas, Nevada (PRWEB) , ... August 04, ... ... INTIMATELY FEMALE, a striking contemporary look at unique artistic expressions from a diverse ... Motel inside the Life Is Beautiful Music & Art Festival on September 25-27, ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... brings an automatic end to driving, says the August 2015 Harvard Health Letter. ... okay to drive. It requires an individual assessment of skills," says Lissa Kapust, ...
Breaking Medicine News(10 mins):Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3Health News:NutraScience Labs "Steps Up" to the 2015 Marcum Workplace Challenge 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2
... artificial heart could prevent death in critically ill patients ... . The artificial heart implant improved survival rates before ... ,The artificial heart was found to be a ... did not improve with standard therapy and who were ...
... drug combined with sunlight helps the body tan quicker without ... that is similar to the body’s hormone that regulates skin ... can induce tanning in human volunteers who are known to ... Researchers conducted three different clinical trials to see if MT-1 ...
... research shows a significant improvement in treatment for a specific ... seminoma is typically treated by // removal of the testicle ... a second cancer in another organ up to 20 years ... a single course of the drug carboplatin and more than ...
... risk of developing a variety of skin conditions such ... many of these problems can be averted by correcting ... instrument. ,Researchers found the most common skin disorders ... of an instrument and irritations caused by prolonged, intense ...
... drug that helps reduce the risk of reactivating the ... with chemotherapy for breast cancer.An estimated 12 percent // ... and these patients are at risk of developing HBV ... in varying degrees of liver damage that may lead ...
... has shed light on how brain controls movement say researchers. ... make its whiskers twitch, a discovery researchers say //could help ... scientists develop devices paralyzed people could control, such as robotic ... the part of the brain that controls movement contains so ...
Cached Medicine News:
(Date:8/3/2015)... 3, 2015 Discovery Laboratories, Inc. (Nasdaq: ... on developing aerosolized KL4 surfactant therapies for respiratory ... at 8:30 a.m. Eastern Time on Tuesday August 11, ... 2015 second quarter financial results along with providing ... press release announcing the second quarter 2015 financial ...
(Date:8/3/2015)... -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), a ... of innovative therapies for the treatment of acute pain, ... for the three and six months ended June 30, ... July 23, 2015, the Committee for Medicinal Products for ... for the management of acute moderate-to-severe post-operative pain in ...
(Date:8/3/2015)... FLINT, Mich., Aug. 3, 2015 Diplomat Pharmacy, Inc. ... announced financial results for the quarter ended June 30, 2015. ... June 30, 2014. Second Quarter 2015 Highlights ... of 49% or $266 million , Total prescriptions dispensed ... of 8.6% versus 5.5% , Adjusted EBITDA of $22.7 ...
Breaking Medicine Technology:Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18
... 2010 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... quarter ended September 30, 2010, on Tuesday, November 9, 2010 ... Company recently held an investor conference call on October 11th, ... with the release of the Company,s third quarter results.  The ...
... The Phase 3 results from the ADVANCE study ... The study reports an improvement in treatment discontinuation rates ... and demonstrates an increase in sustained viral response (SVR) ... endpoint for this study was SVR 24 weeks after ...
Cached Medicine Technology:Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010 2Increased SVR and Decreased Adverse Events Reported in Final Results of Phase 3 Study on Telaprevir 2Increased SVR and Decreased Adverse Events Reported in Final Results of Phase 3 Study on Telaprevir 3
This popular post op shoe provides quality care at an outstanding value. The semi-rigid outsole provides stability and minimizes flexure....
... Specifically designed for patients who experience severe ... Day prevents tears in fibrous tissue that ... during those first steps in the morning. ... the pain associated with plantar fasciitis and ...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
Resilient insole has a series of removable hexagons for tailored pressure relief....
Medicine Products: